Patents by Inventor Marcus Trunk-Gehmacher
Marcus Trunk-Gehmacher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210071267Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: ApplicationFiled: November 2, 2020Publication date: March 11, 2021Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Publication number: 20210047697Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: ApplicationFiled: November 2, 2020Publication date: February 18, 2021Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Patent number: 10697966Abstract: This invention provides methods and kits for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and/or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and/or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition.Type: GrantFiled: September 8, 2014Date of Patent: June 30, 2020Assignee: Ventana Medical Systems, Inc.Inventors: Ruediger Ridder, Wolfgang Rudy, Matthias Herkert, Marcus Trunk-Gehmacher, Anja Reichert, Magnus Von Knebel Doeberitz
-
Publication number: 20200017923Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: ApplicationFiled: September 23, 2019Publication date: January 16, 2020Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Patent number: 8975036Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: GrantFiled: October 29, 2008Date of Patent: March 10, 2015Assignee: Ventana Medical Systems, Inc.Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Publication number: 20150065383Abstract: This invention provides methods and kits for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and/or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and/or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition.Type: ApplicationFiled: September 8, 2014Publication date: March 5, 2015Inventors: RĂ¼diger RIDDER, Wolfgang Rudy, Matthias Herkert, Marcus Trunk-Gehmacher, Anja Reichert, Magnus Von Knebel Doeberitz
-
Patent number: 8367353Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterizing the proliferation properties of the respective cell. The characterization of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: GrantFiled: March 6, 2009Date of Patent: February 5, 2013Assignee: Roche MTM Laboratories AGInventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Publication number: 20090181406Abstract: This invention provides methods and kits for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and/or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and/or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition.Type: ApplicationFiled: March 9, 2009Publication date: July 16, 2009Inventors: Rudiger Ridder, Wolfgang Rudy, Matthias Herkert, Marcus Trunk-Gehmacher, Anja Reichert, Magnus Von Knebel Doeberitz
-
Publication number: 20090176204Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterising the proliferation properties of the respective cell. The characterisation of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: ApplicationFiled: March 6, 2009Publication date: July 9, 2009Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Patent number: 7517662Abstract: This invention provides methods for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and/or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and/or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition.Type: GrantFiled: July 31, 2003Date of Patent: April 14, 2009Assignee: MTM Laboratories, AGInventors: RĂ¼diger Ridder, Wolfgang Rudy, Matthias Herkert, Marcus Trunk-Gehmacher, Anja Reichert, Magnus Von Knebel Doeberitz
-
Publication number: 20090068675Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterising the proliferation properties of the respective cell. The characterisation of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: ApplicationFiled: October 29, 2008Publication date: March 12, 2009Applicant: MTM Laboratories, AGInventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Publication number: 20070128599Abstract: The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterising the proliferation properties of the respective cell. The characterisation of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens.Type: ApplicationFiled: October 21, 2003Publication date: June 7, 2007Inventors: Ruediger Ridder, Anja Reichert, Marcus Trunk-Gehmacher, Richard Batrla
-
Publication number: 20050272038Abstract: The present invention relates to a method for improved diagnosis of cervical lesions based on detection of gene products encoded by the INK4a gene locus. According to the present invention an improvement in diagnosis may be achieved by assessing the presence or absence or the level of overexpression of at least two different gene products encoded by the INK4a gene locus. In another aspect the present invention relates to peptides derived from cell cycle regulatory proteins, the expression of which is altered in association with tumors in individuals. These peptides according to the present invention may be used for detection and therapy of tumors. For detection purposes the peptides may for example be used to detect antibodies directed against said peptides. In therapeutic respect the peptides may be used for immunotherapy or vaccination approaches. In therapeutic and diagnostic respect the peptides may be used in combination with one or more peptides derived from tumor associated proteins.Type: ApplicationFiled: July 17, 2003Publication date: December 8, 2005Inventors: Ruediger Ridder, Peter Martin, Matthias Herkert, Anja Reichert, Marcus Trunk-Gehmacher
-
Publication number: 20040023288Abstract: This invention provides methods for improved diagnosis of medically relevant conditions by solution based biochemical testing procedures performed in solutions of test samples. The invention provides a method to substitute the cell based morphological information contained within the cytological and/or histological data of the test sample by molecular information obtainable from the solution, wherein the original test sample is dissolved and thus enables for accurate and reproducible assessment of medically relevant diagnosis from dissolved test samples. The method according to the invention comprises the steps of determining the levels of one or more disease markers associated with the condition to be diagnosed, determining the level of one or more normalization markers suitable to substitute the information related to morphological aspects of the sample, comparing and/or combining the data of the disease and normalization markers, and assessing diagnosis of a medically relevant condition.Type: ApplicationFiled: July 31, 2003Publication date: February 5, 2004Inventors: Rudiger Ridder, Wolfgang Rudy, Matthias Herkert, Marcus Trunk-Gehmacher, Anja Reichert, Magnus Von Knebel Doeberitz